Home » Stocks » APTO

Aptose Biosciences, Inc. (APTO)

Stock Price: $2.70 USD 0.05 (1.89%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
After-hours: $2.75 +0.05 (1.85%) Jul 28, 7:09 PM
Market Cap 240.15M
Revenue (ttm) n/a
Net Income (ttm) -59.94M
Shares Out 88.94M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $2.70
Previous Close $2.65
Change ($) 0.05
Change (%) 1.89%
Day's Open 2.61
Day's Range 2.59 - 2.76
Day's Volume 583,735
52-Week Range 2.55 - 7.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlyi...

1 week ago - GlobeNewsWire

Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or ref...

1 month ago - Benzinga

SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...

1 month ago - GlobeNewsWire

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other stocks mentioned: FBIO, MBIO, RGLS
1 month ago - PennyStocks

SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...

1 month ago - GlobeNewsWire

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS

2 months ago - GlobeNewsWire

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyin...

2 months ago - GlobeNewsWire

- Conference call and webcast at 4:30 pm EDT today -

2 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underly...

3 months ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CRON, KGC, CMRE, LOTZ
3 months ago - 24/7 Wall Street

SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underly...

3 months ago - GlobeNewsWire

Aptose Biosciences Inc. (NASDAQ: APTO) shares traded higher after the company's release of fourth-quarter results Tuesday.  The stock gained 66.21% in Wednesday's regular session, closing at $6.10.

4 months ago - Benzinga

The company reported very encouraging results from an early-stage study.

4 months ago - The Motley Fool

APTO stock is rocketing this morning as the company releases some encouraging research details alongside its Q4 earnings report. The post APTO Stock: Why Aptose Biosciences Is Rocketing Higher Today app...

4 months ago - InvestorPlace

- Conference call and webcast at 5pm EDT today -

4 months ago - GlobeNewsWire

George Melko, Pharm.D. joins as Vice President, Regulatory Affairs

4 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underly...

4 months ago - GlobeNewsWire

Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.

6 months ago - Zacks Investment Research

Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lower doses of...

7 months ago - Seeking Alpha

SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th,...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers

7 months ago - GlobeNewsWire

Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.

Other stocks mentioned: FPRX
8 months ago - The Motley Fool

Aptose shares have been weak of late, but there have been no negative updates to the company's core clinical programs, and management recently started its third trial (CG-806 in AML). It is unclear whet...

8 months ago - Seeking Alpha

Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level

8 months ago - GlobeNewsWire

Abstracts Accepted for Presentation Abstracts Accepted for Presentation

8 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...

9 months ago - GlobeNewsWire

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

9 months ago - Zacks Investment Research

Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg

9 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the under...

10 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the under...

10 months ago - GlobeNewsWire

Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

APTO's lead candidate, CG-806, is due for important updates in 4Q2020.

11 months ago - Seeking Alpha

SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlyi...

11 months ago - GlobeNewsWire

Aptose has recently raised more cash, and looks set for its foreseeable clinical trial needs.

11 months ago - Seeking Alpha

Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underl...

1 year ago - GlobeNewsWire

Dilution is on the way.

1 year ago - The Motley Fool

SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public offer...

1 year ago - GlobeNewsWire

Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML

1 year ago - GlobeNewsWire

Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?

Other stocks mentioned: SRPT, VIE
1 year ago - The Motley Fool

Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies

1 year ago - GlobeNewsWire

SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therape...

1 year ago - GlobeNewsWire

Aptose Biosciences' (APTO) CEO William Rice on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents t...

1 year ago - GlobeNewsWire

Data from patients at first two dose levels; Phase 1a/b study is ongoing Data from patients at first two dose levels; Phase 1a/b study is ongoing

1 year ago - GlobeNewsWire

Aptose Riding Higher As The Street Starts Paying Attention

1 year ago - Seeking Alpha

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the t... [Read more...]

Industry
Biotechnology
Founded
1986
CEO
William Rice
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
APTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for APTO stock is "Buy." The 12-month stock price forecast is 4.72, which is an increase of 74.81% from the latest price.

Price Target
$4.72
(74.81% upside)
Analyst Consensus: Buy